Evaluation of the impact of refined nursing care on schizophrenia patients.

This study evaluates the impact of refined nursing interventions on patients with schizophrenia, focusing on disease severity, cognitive function, medication adherence, quality of life, and medication-related complications. The aim is to provide evidence for enhancing future clinical treatments. From January 2022 to January 2024, 201 schizophrenia patients were enrolled based on specific inclusion and exclusion criteria. Patients were allocated into 2 groups using propensity score matching: an experimental group that received refined nursing care and a control group that received routine care. Outcome measures included Positive and Negative Syndrome Scale scores, cognitive assessments (Mini-Mental State Examination and Nurses' Observation Scale for Inpatient Evaluation), medication adherence, quality of life, relapse rates, and medication-related side effects. After propensity score matching, baseline characteristics of the experimental and control groups were comparable. Following nursing interventions, the experimental group demonstrated significant improvements in Positive and Negative Syndrome Scale scores, cognitive assessments (Mini-Mental State Examination and Nurses' Observation Scale for Inpatient Evaluation), medication adherence, and quality of life compared to the control group. The experimental group also showed lower relapse rates and fewer medication side effects, confirming the enhanced effectiveness of refined nursing interventions. Refined nursing care significantly improved disease outcomes, cognitive function, medication adherence, and quality of life in schizophrenia patients, while reducing relapse rates and medication-related complications, highlighting its clinical value in psychiatric care.